A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Clinical trial NCT06852222 · RECRUITING
Trial details
- NCT number
- NCT06852222
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-04
- Primary completion
- 2029-06-22
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.